Mesenchymal stem cells (MSCs) have recently made significant progress with multiple
clinical trials targeting modulation of immune responses, regeneration of bone, cartilage …

The constant supply of high cell numbers generated by defined, robust, and economically
viable culture processes is indispensable for the envisioned application of human …

Development of a human embryonic stem cell (hESC)-based therapy for type 1 diabetes will
require the translation of proof-of-principle concepts into a scalable, controlled, and …

Human pluripotent stem cells (hPSCs), including human embryonic stem cells and induced
pluripotent stem cells, are promising for numerous biomedical applications, such as cell …

Human pluripotent stem cells (hPSCs), including embryonic and induced pluripotent stem
cells, constitute an extremely attractive tool for cell therapy. However, flexible platforms for …

To harness the potential of human pluripotent stem cells (hPSCs), an abundant supply of
their progenies is required. Here, hPSC expansion as matrix-independent aggregates in …

Human embryonic stem cells and induced pluripotent stem cells have great potential in
research and therapies. The current in vitro culture systems for human pluripotent stem cells …

Current practices to maintain human pluripotent stem cells (hPSCs), which include induced
pluripotent stem cells and embryonic stem cells, in an undifferentiated state typically depend …

Routine commercial and clinical applications of human pluripotent stem cells (hPSCs) and
their progenies will require increasing cell quantities that cannot be provided by …

To meet the need of a large quantity of hPSC-derived cardiomyocytes (CM) for pre-clinical
and clinical studies, a robust and scalable differentiation system for CM production is …